S1474
Interdisciplinary - Patient involvement
ESTRO 2026
comparisons by Kruskal–Wallis tests across four treatment pathways. Results: All patients completed RT and serial assessments. Scores demonstrated mid-treatment deterioration with post-treatment recovery. HADS median total score rose from 4.0 to 7.0 at week 2, then declined to 2.0 at three months (p < 0.001). FACT-H&N QoL dropped by 18 points at week 2 (p < 0.001) with partial recovery; emotional and functional domains were most affected. Distress peaked at 6 on NCCN-DT (baseline 3; p < 0.001), with 68% showing clinically significant distress. ESAS symptoms (pain, fatigue, xerostomia, dysphagia) peaked at week 2, correlating with HADS subscales (r ≈ 0.45, p < 0.01). Conclusion: Concurrent use of PROMs identified a consistent distress peak in the second week of RT. Early intervention enabled timely treatment completion, preserved QoL and reduced invasive supportive procedures. References: 1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–70. doi:10.1111/j.1600- 0447.1983.tb09716.x. PMID: 6880820.2. Chandra RA, Li RJ, editors. Multidisciplinary Management of Head and Neck Cancer. Cham: Springer International Publishing; 2022. 3. Li PC, Margalit DN. Overview of head and neck cancer management. In: Improving the Therapeutic Ratio in Head and Neck Cancer. Elsevier; 2020. p. 1– 32.4. Sahu S, Ramawat Y, Kumawat N, Sahu R, Kumar V, Nath M. Holistic care approach for the effective management of severe radiation dermatitis using neem (Azadirachta indica) and honey after head–and- neck radiotherapy. Indian J Palliat Care. 2020;26(4):540. Keywords: HADS, QOL (Quality of Life), RT-toxicities Associations of diagnosis and engagement with a digital ePRO tool deployed in routine radiation oncology practice Cas Stefaan Dejonckheere 1 , Ian Kudel 2 , Annette Christianson 2 , Shari Wiegreffe 1 , Andrea Renate Glasmacher 1 , Markus Zeller 1 , Mario Kossmann 1 , Julian Philipp Layer 1 , Zoya Shamsi 2 , Eleni Gkika 1 , Davide Scafa 1 1 Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany. 2 Varian, a Siemens Healthineers Company, Palo Alto, USA Purpose/Objective: To assess patient-reported satisfaction and engagement with Noona, a secure, bidirectional, Poster Discussion 1471
cloud-based electronic patient-reported outcomes (ePRO) platform used by patients undergoing radiotherapy at our site. Material/Methods: This archival study (n=122) included patients with prostate (n=43; 35.25%), breast (n=37; 30.33%), brain (CNS; n=15; 12.30%), and other cancers (n=27; 22.13%) receiving standard-of-care radiotherapy. Participants submitted weekly status updates using validated, disease-specific HRQoL instruments, and accessed diary and clinical care team communication features as needed. After treatment, they completed a satisfaction questionnaire assessing usage (frequency, features), perceived impact (improved treatment experience, reduced stress), and intent to continue using the app during follow-up via a 5-point Likert scale. Descriptive analyses and cumulative logit ordinal regressions tested the associations between age, diagnosis, usage frequency, and feature use with satisfaction outcomes. Results: App users were evenly split across sex (n=62; 50.82% female) and were middle-aged (median=63; range=30- 88 years). More than half reported using the app weekly (Table 1). Most used it to report symptoms. More than half reported Noona had a positive impact and decreased stress; most planned to use it during follow-up.The first regression, predicting the positive impact of the ePRO platform on a patient’s therapy, found that daily app users were significantly more likely (5.12 times) to report a higher impact category compared to weekly users, whereas monthly users were significantly less likely (by 87%) to report a higher
impact category than weekly users (Table 1). Additionally, breast and CNS patients were
significantly less likely (by 71% and 78%, respectively) to report a higher impact level than prostate cancer patients.Next, daily app users were significantly more likely (4.42 times) to report a higher level of stress relief using Noona compared to weekly users; conversely, monthly users were significantly less likely (76%) to select a higher category.Finally, patients who used the secure communication feature were significantly more likely (2.52 times) to report a higher level of future app use compared to nonusers. Also, monthly users were significantly less likely (75%) to report a higher level of interest in follow-up app usage than weekly users. Users with brain tumors were also significantly less likely (54%) to report a higher level of interest in continuing app usage in comparison with prostate patients.
Made with FlippingBook - Share PDF online